Society of Hematologic Oncology

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Society of Hematologic Oncology

Free SOHO Membership: www.sohoonline.org

SOHO 2023
Leukemia Lymphoma Myeloma MDS and MPN Videos
SOHO 2022
Myeloma Lymphoma Leukemia MDS and MPN Benign Hematology
SOHO 2021
Myeloma Cellular Therapy Solid Tumors Leukemia MDS Benign Hematology MPN Lymphoma
SOHO 2020
Basic Science Lymphoma Leukemia Myeloma MDS and MPN Benign Hematology
SOHO Highlights: State of the Art and Next Questions
SOHO 2019
Hodgkin Lymphoma Multiple Myeloma Chronic Lymphocytic Leukemia Meet The Professor Sessions Chronic Myeloid Leukemia Myeloproliferative Neoplasms Breakfast With The Expert Independent Satellite Symposium Plenary Sessions Evolving Practices in AML: A Case-based Guide to New and Emerging Treatment Options Acute Lymphoblastic Leukemia Myelodysplastic Syndromes Acute Myeloid Leukemia Indolent B-cell Lymphoma Mantle Cell Lymphoma Aggressive B-cell Lymphoma T-cell Lymphoma Cellular Therapy Next Questions
SOHO 2018
Session I: Chronic Myeloid Leukemia Session II: Myelodysplastic Syndromes Session III: Myeloproliferative Neoplasms Session IV: Acute Lymphoblastic Leukemia Session V: Acute Myeloid Leukemia Session VI: Multiple Myeloma Session VIII: Non-Hodgkin Lymphoma Session IX: Chronic Lymphocytic Leukemia Session X: Research Topics Plenary Sessions Breakfast with the Expert
Events

Playback speed

10 seconds

2020 SOHO Highlights De-Intensified vs. Intensified Treatment in Ph+ ALL: What Are the Long Term EFS/OS Outcomes? What Is the MRD Negativity Rate With Dasatinib and Blinatumomab?

By Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020) FEATURING Sabina Chiaretti

13 views

November 13, 2020

Comments 0

The First Treatment Choice Matters

Feat. A. Ip

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Leukemia

How I Treat Older Adults With B-ALL in 2020: Is OS Better With Blina…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

E. Jabbour

21 views

2020 SOHO Updates on Adult ALL: Is There a Role for Venetoclax in ET…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

N. Jain

327 views

2020 SOHO Highlights on AlloHCT in R/R ALL: Is Survival Following Po…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

L. Muffly

52 views

2020 SOHO Updates on AML: Are IDH Inhibitors Safe to Combine With In…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

S. De Botton

13 views

2020 SOHO Updates on R/R AML: Is Gilteritinib Superior to Chemo in F…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

C. Smith

130 views

2020 SOHO Highlights on MRD in AML: Clonal Structures/Selection of S…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

V. Paresh Vyas

10 views

2020 SOHO Update on COG Approach to High-Risk ALL: What Is the Best …

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

J. Mcneer

12 views

2020 SOHO Update on Asparaginase-Related Toxicity in AYAs With ALL: …

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

K. Schmiegelow

21 views

2020 SOHO Update on AYAs With ALL: How to Use an MRD Result in Patie…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

A. Logan

20 views

Acalabrutinib vs. SoC for R/R CLL: Do the Final Results of ASCEND Tr…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

P. Ghia

65 views

2020 SOHO Updates on CAR-T Therapy in CLL: Are Toxicities Acceptable…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

E. Shpall

18 views

2020 SOHO Update on Initial Therapy in CLL: Can We Consider BTK Inhi…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

M. Hallek

80 views

Treatment Consideration of CLL: Evaluation of BTK Inhibitor in the F…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

J. Byrd

124 views

2020 SOHO Update on Familial AML: What Are the Current Recommendatio…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

C. DiNardo

12 views

2020 SOHO Update on Targeting Microenvironment in R/R AML: CXCR4 Inh…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

G. Uy

12 views

2020 SOHO Paradigm Changes in Newly Diagnosed AML: Is Venetoclax a G…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

D. Pollyea

57 views

2020 SOHO Expert Q&A on AML: Familial AML, Targeting Microenvironmen…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

D. Pollyea, G. Uy, C. DiNardo

32 views

2020 SOHO Update on CAR-T for R/R AML: What Are the Current Limitati…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

E. Budde

34 views

2020 SOHO Update on Ven+Aza in Induction AML: Does This Combo Extend…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

C. DiNardo

34 views

2020 SOHO Update on Novel Antibodies in AML: Target Antigens, Approv…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

M. Subklewe

53 views

2020 SOHO Update on Germline Mutations in AML: Who Should Be Screene…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

C. Lindsley

13 views

2020 SOHO Update on AYA Ph- ALL: Can an Adult Hematologist Utilize a…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

S. Eldadah

15 views

Intensive vs. Non-Intensive Approach in Adults With Ph+ ALL: Does Ch…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

S. Chiaretti

14 views

Intensive vs. Non-Intensive Approach in Adults With Ph+ ALL: Is Inte…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

N. Short

18 views

2020 SOHO Updates on AlloHSCT in AML: Are There Benefits to Chemo in…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

U. Borate

119 views

2020 SOHO Highlights on AlloSCT in AML: Which Older Patients in Firs…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

E. Alyea

231 views

2020 SOHO Highlights on CD123 in AML: What Determines Sensitivity an…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

A. Lane

80 views

2020 SOHO Updates on AML: Is Delaying Treatment Dangerous? What Are …

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

L. Michaelis

83 views

2020 SOHO Highlights De-Intensified vs. Intensified Treatment in Ph+…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

S. Chiaretti

13 views

2020 SOHO Updates on Ph+ ALL: What Is the Effect of CMR on OS? Is Hy…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

N. Short

161 views

2020 SOHO Updates on AML: Are Venetoclax+HMA Combinations Safe and E…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

M. Konopleva

123 views

2020 SOHO Highlights on CAR-T in ALL: What Are the Desired Character…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

M. Pule

60 views

2020 SOHO Updates on R/R ALL: Inotuzumab Ozogamicin, Blinatumomab, &…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

E. Curran

33 views

2020 SOHO CP-CML Update: How Effective Is 50mg Daily Dasatinib in Ne…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

M. Deininger

11 views

2020 SOHO Update on CP-CML: Can Personalization of TKI Treatment Opt…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

D. Rea

18 views

2020 SOHO Updates on CML: Are There Differences in Treatment Respons…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

J. Cortés

10 views

2020 SOHO Update on CML-Like Disorders: Comparing Treatment Efficacy…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

N. Cross

227 views

2020 SOHO Updates on AML: How Is Drug Development Affecting Treatmen…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

A. Zeidan

31 views

2020 SOHO Highlights on ALL: Why Does Chemo Not Work for Older Adult…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

M. Luskin

11 views

Next Questions in ALL in 2020: Who Needs a Transplant and When? How …

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

S. Luger

20 views

Next Questions in CLL in 2020: Is Ibrutinib the Best BTK Inhibitor? …

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

J. Brown

319 views

2020 SOHO Update on CML: Is ITH Important in CML? How Does TMB Influ…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

J. Radich

7 views

2020 SOHO ENESTnd Trial Update on Biomarkers in CML: Does Gene Expre…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

J. Radich

71 views

2020 SOHO Next Steps in CML: How Can We Improve the Success of Treat…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

M. Deininger

12 views

2020 SOHO Highlights on Fitness in CLL: What Is the Role of Comorbid…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

A. Tedeschi

211 views

2020 SOHO Update on ALL: What Is the Role of AlloSCT in Ph+ Disease?…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

J. Ribera

12 views

2020 SOHO Updates on MRD in CLL: How Does It Correlate With Clinical…

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

W. Wierda

46 views

2020 SOHO Updates on BCR Inhibitors in CLL: How Do ARQ531, LOXO-305 …

Society of Hematologic Oncology Eighth Annual Meeting (SOHO 2020)

P. Ghia

92 views